5007 articles
A major ESC scientific statement distills the latest evidence on diet, nutrients, and eating patterns for cardiovascular disease prevention.
A new 86-protein score called HPS predicts healthspan with greater accuracy than existing biological age clocks across 53,000 UK Biobank participants.
A first-in-class GLP-1/GIP/glucagon triple agonist shows superior weight loss and metabolic benefits over existing therapies in phase I/II trials.
Researchers built a machine learning imaging pipeline to detect cerebral microhemorrhages and tested SS-31 (elamipretide) in aged hypertensive mice.
A comprehensive GeneReviews update on Barth syndrome outlines diagnosis, new targeted therapy, and surveillance strategies for this rare X-linked disorder.
A comprehensive review of pathophysiology, genetics, and emerging therapies for mitochondrial myopathies, spotlighting elamipretide and gene therapy.
The first disease-specific treatment for Barth syndrome gains FDA accelerated approval, targeting mitochondrial dysfunction to restore muscle strength.
Deleting GTPBP3 in endothelial cells blocks angiogenesis via mtROS overload — and a mitochondria-targeted antioxidant reverses the damage.
A comprehensive review in CA Cancer J Clin maps the molecular biology, treatment strategies, and equity gaps in high-grade serous ovarian cancer.
Mendelian randomization links circulating inflammatory proteins to retinal microvascular changes, heart disease risk, and lifespan — establishing causal direction.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
A 2025 review maps the molecular mechanisms driving cardiovascular aging—from inflammaging to ECM remodeling—and outlines emerging therapies.
